Multiple Myeloma | Specialty

PVd Regimen Highlighted as New Standard in Relapsed/Refractory Myeloma

July 13th 2018

Paul Richardson, MD, discusses the efficacy and tolerability of the combination of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone in patients with multiple myeloma.

Maintenance Ixazomib Improves PFS in Multiple Myeloma

July 11th 2018

Ixazomib (Ninlaro) improved progression-free survival compared with placebo as a maintenance therapy in adult patients with multiple myeloma who responded to high-dose therapy and autologous stem cell transplant.

Dr. Richardson on the Synergy Between Immunomodulators and Proteasome Inhibitors

July 6th 2018

Paul Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the synergy between immunomodulators and proteasome inhibitors in the treatment of patients with relapsed/refractory multiple myeloma (RRMM).

Expert Discusses Daratumumab Developments in Myeloma

July 6th 2018

Ajai Chari, MD, discusses the addition of daratumumab to carfilzomib and dexamethasone, as well as the potential impact of subcutaneous daratumumab in the treatment of patients with myeloma.

Dr. Chari on the Subgroup Analysis of MMY1001 in Multiple Myeloma

June 29th 2018

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the subgroup analysis of MMY1001 in multiple myeloma.

Dr. Gay Discusses the Efficacy Data from the FORTE Trial in Myeloma

June 28th 2018

Francesca Gay, MD, PhD, hematologist, Myeloma Unit, Division of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, discusses the updated efficacy data from the FORTE trial of patients with newly-diagnosed multiple myeloma.

Dr. Pecora on the Role of Stem Cell Transplant in Patients With Multiple Myeloma

June 23rd 2018

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the role of stem cell transplant in patients with multiple myeloma.

Elotuzumab/Pomalidomide Prolongs PFS in Pretreated Multiple Myeloma

June 17th 2018

The addition of elotuzumab to pomalidomide and dexamethasone cut the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

Dr. Biran on Patient-Reported Outcomes Following Transplant in Multiple Myeloma

June 14th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses patient-reported outcomes following autologous stem cell transplantation in multiple myeloma.

FDA Adds Survival Data to Carfilzomib Myeloma Label

June 12th 2018

The FDA approved a supplemental new drug application adding overall survival data from the phase III ASPIRE trial to the label for carfilzomib for use in patients with relapsed or refractory multiple myeloma.

Dr. Costa on Triplet of Venetoclax, Carfilzomib, and Dexamethasone in Multiple Myeloma

June 3rd 2018

Luciano J. Costa, MD, PhD, associate professor of medicine, Blood and Marrow Transplantation and Cell Therapy Program, University of Alabama at Birmingham School of Medicine, discusses phase II findings with the triplet regimen of venetoclax (Venclexta), carfilzomib (Kyprolis), and dexamethasone in patients with relapsed/refractory multiple myeloma. Costa shared this insight in an interview with OncLive during the 2018 ASCO Annual Meeting.

Pembrolizumab Studies Show Disparate Data on Link Between AE and Response in Multiple Myeloma

June 2nd 2018

Pembrolizumab (Keytruda) yielded inconsistent results regarding the relationship between immune-related adverse events and objective response in multiple myeloma.

Once Weekly Carfilzomib Superior in Relapsed/Refractory Myeloma

June 2nd 2018

Carfilzomib (Kyprolis) administered once weekly at 70 mg/m2 with dexamethasone resulted in a prolonged PFS compared with the standard twice-weekly schedule in patients with relapsed/refractory multiple myeloma.

bb2121 Adds Nearly 1 Year of PFS for Heavily Pretreated Myeloma

June 2nd 2018

bb2121 had a median progression-free survival of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated multiple myeloma.

Practice Changes for Use of Immunotherapy in NSCLC: Q&A

June 2nd 2018

Using Immunotherapy Beyond Progression in NSCLC

June 2nd 2018

Optimizing Immunotherapy in the NSCLC Treatment Paradigm

June 2nd 2018

Tumor Mutational Burden in NSCLC: Should it be Routine?

June 2nd 2018

Impact of Data on the Real-Life Treatment of NSCLC

June 2nd 2018

Important Data in the Squamous NSCLC Population

June 2nd 2018